20:01 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Renal; cardiovascular; hepatic

INDICATION: Renal failure; heart failure; liver failure Mouse studies suggest inhibiting YY1 or its co-repressor FKBP12 could help treat chronic renal, heart and liver failure. In a mouse model of urethral obstruction-induced chronic renal failure,...
20:30 , Jan 13, 2017 |  BC Week In Review  |  Company News

Selten, Vivus deal

Selten granted Vivus exclusive, worldwide rights to develop and commercialize tacrolimus and ascomycin to treat pulmonary arterial hypertension (PAH) and related vascular diseases. Selten had rights to patents covering the drugs from Stanford University (Stanford,...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Company News

Medivir, Valeant Pharmaceuticals, Meda sales and marketing update

Medivir and Meda amended a 2010 commercialization deal for Medivir's Xerese to treat herpes simplex labialis (cold sores) to grant Meda full rights to the product in North America plus exclusive U.S. rights to treat...
01:21 , Jul 1, 2011 |  BC Extra  |  Company News

Meda, Valeant in deal for topical drugs

Meda AB (SSE:MEDAA) granted Valeant Pharmaceuticals International Inc. (NYSE:VRX; TSX:VRX) exclusive rights in North America to topical eczema drug Elidel pimecrolimus and topical herpes drug Xerese acyclovir/hydrocortisone. The partners plan to collaborate on the two...
07:00 , May 16, 2011 |  BC Week In Review  |  Company News

Meda, Novartis sales and marketing update

Meda completed its previously announced acquisition of dermatology drug Elidel pimecrolimus from Novartis for $420 million in cash. The non-steroidal ascomycin derivative 1% cream is marketed to treat atopic dermatitis (eczema) in more than 90...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Meda, Novartis sales and marketing update

Meda will acquire dermatology drug Elidel pimecrolimus from Novartis for $420 million in cash. The non-steroidal ascomycin derivative 1% cream is marketed to treat atopic dermatitis (eczema) in more than 90 countries, including the U.S....
00:30 , Apr 8, 2011 |  BC Extra  |  Company News

Meda acquires Elidel from Novartis

Meda AB (SSE:MEDAA) will acquire dermatology drug Elidel pimecrolimus from Novartis AG (NYSE:NVS; SIX:NOVN) for $420 million in cash. The non-steroidal ascomycin derivative 1% cream is marketed in more than 90 countries, including the U.K.,...
07:00 , Apr 3, 2006 |  BC Week In Review  |  Clinical News

Elidel pimecrolimus regulatory update

CHMP recommended the cautious use of Elidel, a non-steroidal pimecrolimus (ascomycin derivative) 1% cream, to treat atopic dermatitis. The committee concluded that the benefits associated with the use of Elidel outweigh the risks, but that...
07:00 , Oct 24, 2005 |  BC Week In Review  |  Clinical News

Elidel pimecrolimus dermatology data

In an international trial in 200 patients allergic to steroids, 46.5% of the Elidel group vs. 16.2% of the vehicle cream group were "clear or almost clear" of facial eczema at 6 weeks (p<0.001), with...
07:00 , Oct 24, 2005 |  BC Week In Review  |  Clinical News

Elidel pimecrolimus dermatology data

Data from the 26-week, double-blind, vehicle-controlled (PEP study4) trial in 543 adult patients showed that the mean number of flare-ups was reduced to 0.97 with Elidel vs. 1.39 for control. Median time to first flare...